COVID-19 | Insights

Embracing collaboration in the fight
against COVID-19

Accelerating the expansion of what we know about COVID-19 is critical to conquering the pandemic. The world needs faster testing, faster vaccine development, faster results — but how?

The scientific and medical research communities stand united in their steadfast efforts to find not just a vaccine, but other effective therapeutics such as antiviral drugs, peptide inhibitors, nucleoside analogues, and monoclonal antibodies. We have never been more honored to stand with them.

Explore Solutions for COVID-19

Accelerating your efforts to combat infectious disease

COVID-19 Insights: Articles

Filter by: All Research Vaccine and Drug Development Testing Development

New

Research, Testing Development

Hiroshima University utilizes automation to speed up novel coronavirus testing

Hiroshima University researchers led by Dr. Hidetoshi Tahara, Dr. Junko Tanaka, Dr. Takemasa Sakaguchi, Professor Hideki Ohdan, and Professor Hiroki Ohge recently implemented an automated sample preparation system, as sample prep is a major bottleneck in testing and analyzing the COVID-19 virus.
New

Research, Vaccine and Drug Development, Testing Development

Researchers Develop COVID-19 Severity Screening Method Based on the Agilent Cary 630 FTIR Spectrometer

Agilent Technologies Inc. (NYSE: A) announces that researchers at the Indian Institute of Technology Bombay in India and the QIMR Berghofer Medical Research Institute in Australia have developed a rapid method for differentiating COVID-19-positive patients expected to show severe symptoms from those likely to experience only mild symptoms.
New

Research, Vaccine and Drug Development

The Need for Vigilance: Novel Variants and Vaccine Breakthroughs

A little over a year ago, the World Health Organization officially declared COVID-19 a pandemic. Twelve months after that announcement, we witnessed the development and FDA Emergency Use Authorization issuance of two novel RNA vaccines and one adenoviral vector vaccine.
New

Research

Developing a Serological Test to Detect SARS-CoV-2 Clues

Icahn School of Medicine at Mount Sinai in New York City develops a highly specific and sensitive ELISA protocol to detect SARS-CoV-2 antibodies in human serum.
New

Research, Vaccine

From Concept to Clinic: How SARS-CoV-2 Vaccines Are Helping Forge a Path out of the Pandemic

In December 2020, amid a renewed surge of SARS-CoV-2 cases that saw COVID-19 pandemic deaths top more than 1.6 million people worldwide, we heard the news we had been waiting for: a vaccine had finally been approved.
Trending

Research

New Tool Identifies Thousands of Known and Unknown Pathogens: A Weapon in the Fight Against COVID-19 and Beyond

Ever since the first microbes were identified by microscopy in the 17th century, we have learned just how involved microbes are in the regulation of physical environments and living things, both beneficial and harmful.
Trending

Research

Using Agilent's Certified Pre-Owned Instruments to Research the Prediction of COVID-19

What if predicting where and when a COVID-19 outbreak would occur were possible? Not just project the virus' trajectory but forecast where and when to expect a wave of positive cases. That's exactly what Denina Simmons is researching at Ontario Tech University in Canada.

Research

Examining Viral Respiratory Diseases

Agilent's Cell Analysis division has recently awarded an xCELLigence Research Grant to a leading science and technology agency in Australia. The principal scientist of this infectious disease research lab will employ xCELLigence real-time cell analysis (RTCA) technology for research of high-throughput screening of therapeutics against respiratory viruses, including SARS-COV-2.

Research, Vaccine and Drug Development

When Time is of the Essence, Fast-Tracking Sample Preparation Can Make All the Difference

Research to block or treat SARS-CoV-2 infection has intensified the interest in developing targeted monoclonal antibodies (mAbs) – a key weapon our bodies produce to fight viruses. The development of targeted mAbs relies on the screening of hundreds to thousands of variants to identify lead candidates for further investigation. Agilent quickly introduced a three-second prescreening step with existing technology.

Research

Streamlining lab work in these challenging times

Tools such as laboratory information management systems (LIMS) and electronic laboratory notebooks (ELNs), among other solutions, can help mitigate the impact on life in the lab. Not only can these systems streamline lab operations, they can also help labs fulfill emergency requests from research laboratories who need to ramp up their operations urgently.

Research, Vaccine and Drug Development, Testing Development

Analysis of Nonmedical Masks

The use of personal protective equipment (PPE) and masks plays a critical role in prevention and control of the spread of certain respiratory infections. During the coronavirus disease (COVID-19) pandemic, the World Health Organization (WHO) released advice on the use of medical and nonmedical masks in the context of COVID-19.

Research, Vaccine and Drug Development

Paving the way out of the pandemic

Since the advent of antibiotics in the mid-19th century provided the ability to cure nearly any bacterial infection, to breakthrough vaccination approaches against diphtheria or tetanus, life-threatening diseases have shifted from bacterial and viral causes to mutated human cells, (e.g., cancer).

Research

Automation to meet the challenges of COVID-19 research

Clinicians and researchers face daunting questions of how to scale testing to meet demand. Research laboratories accustomed to processing a few handfuls of samples a day are now being asked to process thousands as they seek solutions to this crisis.

Research

Small yet powerful: Agilent magnetic beads

Agilent's legacy is largely built on the high-quality instruments we produce, which are found in labs around the world. However, the urgent need for COVID-19 testing has led to a surge in demand for one of our lesser-known products: magnetic beads.

Vaccine and Drug Development

COVID-19 drug development: A therapeutic prescription drug overview

This overview presents a quick summary of journal articles published by various authors on small-molecule drugs that are being repurposed for COVID-19 treatment in clinical trials around the world.
Trending

Research, Vaccine and Drug Development, Testing Development

Inoculating your lab against future disruptions

The current pandemic is causing many in management positions to reassess their ability to respond to unforeseen changes. What can we do to prepare for whatever comes?

Vaccine and Drug Development

COVID-19 treatment: Biotherapeutics and critical quality attribute testing

At the time of writing, there are no vaccines or therapies available for the prevention or cure of COVID-19. Many promising avenues are being investigated, including the use of mAbs as a blocking agent to neutralize the SARS-CoV-2 virus.

Vaccine and Drug Development

Understanding SARS-CoV-2 tools to further knowledge

Structural Genomics Consortium (SGC) at Oxford University and Agilent collaborate to help develop robust and reliable methods to analyze SARS-CoV-2 spike proteins.

Vaccine and Drug Development

COVID-19 vaccine development and separation-based analytical characterization tools

In this article, we look at examples from each vaccine class where chromatographic separations have helped in the characterization of vaccines.

Research

Immune response and the COVID-19 virus

COVID-19 affects people of all ages, races, and genders across the globe. But the degree to which each person reacts to the intrusion of the virus has varied drastically.

Research

Supporting the rapid development of a COVID-19 antibody test

As the response to the COVID-19 pandemic continues, officials and researchers have made a concentrated push to ramp up testing efforts. Testing helps inform us of the virus' prevalence and can give us insight into how the virus has spread and whether it has accumulated potentially relevant mutations.

Testing Development

Work together, work fast

Collaborations within the greater virology community, including academic institutions, are accelerating the development of an antibody discovery program and get it into the clinic.

Research

Addressing an evolving threat with a target enrichment-based NGS approach

Identifying and linking viral mutations to observations in geographic origin, infectivity, and symptoms is helping researchers model how the virus has spread and how it may behave.

Research

Seeking understanding: Researchers look at the impact on immune systems

Tufts University Graduate School of Biomedical Sciences, using BioTek (now a part of Agilent) instruments, seeks to understand the immune system response when facing a threat like the novel coronavirus.

Testing Development

COVID-19 insights: The need for speed

Faster results and faster action are needed to help prevent the spread of COVID-19. See how laboratories are reducing time-to-results from days to hours.

Testing Development

Better together: How working together accelerates coronavirus research

Scientists working together have already made inroads not only on vaccine development efforts, but also on the ongoing impact of the novel coronavirus.

Research

Customer spotlight: Live SARS-CoV-2 research – interlocking pieces working together

At Boston University's National Emerging Infectious Diseases Laboratories (NEIDL), microbiologists, virologists, and other scientists have dropped their routine research projects to focus on the critical search for COVID-19 vaccines and treatments.

For Research Use Only. Not for use in diagnostic procedures.

Disclaimer: Agilent products are NOT authorized for COVID-19 testing, diagnosis, treatment, or mitigation. Agilent has not validated a product to detect the novel coronavirus.

COVID-19 Topics

COVID-19 Insights

Embracing collaboration in the fight against COVID-19

Digital Solutions

Maintain productivity with remote digital solutions

Lab Operations During COVID-19

Support Resources for Getting Your Lab Back Up and Running

Employee Response

See Agilent people finding new ways to meet community needs

Frequently Asked Questions

Learn how to stay productive when facing reduced time in the lab

COVID-19 Media Room

See how Agilent solutions are helping customers combat COVID-19
COVID-19 Home